Statera Biopharma Analysis
Statera Biopharma is undervalued with Real Value of 0.0 and Hype Value of 0.0. The main objective of Statera Biopharma pink sheet analysis is to determine its intrinsic value, which is an estimate of what Statera Biopharma is worth, separate from its market price. There are two main types of Statera Biopharma's stock analysis: fundamental analysis and technical analysis.
The Statera Biopharma pink sheet is traded in the USA on PINK Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Statera Biopharma's ongoing operational relationships across important fundamental and technical indicators.
Statera |
Statera Pink Sheet Analysis Notes
About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.16. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Statera Biopharma recorded a loss per share of 0.76. The entity had not issued any dividends in recent years. The firm had 1:20 split on the 28th of January 2015. Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropeniaanemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the bodys immune system and restore homeostasis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 46 people.The quote for Statera Biopharma is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. To find out more about Statera Biopharma contact Michael Handley at 888 613 8802 or learn more at https://www.staterabiopharma.com.Statera Biopharma Investment Alerts
Many investors view ongoing market volatility as an opportunity to purchase more pink sheets at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Statera Biopharma's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Statera Biopharma or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
| Statera Biopharma is not yet fully synchronised with the market data | |
| Statera Biopharma has some characteristics of a very speculative penny stock | |
| Statera Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Statera Biopharma currently holds 10.62 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Statera Biopharma has a current ratio of 0.05, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Statera Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Statera Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Statera Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Statera to invest in growth at high rates of return. When we think about Statera Biopharma's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 1.49 M. Net Loss for the year was (101.88 M) with profit before overhead, payroll, taxes, and interest of 998.72 K. | |
| Statera Biopharma currently holds about 506.1 K in cash with (28.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 16.0% of Statera Biopharma outstanding shares are owned by corporate insiders |
Statera Biopharma Thematic Classifications
In addition to having Statera Biopharma pink sheet in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
 | BiotechBiotechnology and pharmaceuticals production and services |
Statera Market Capitalization
The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.97 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Statera Biopharma's market, we take the total number of its shares issued and multiply it by Statera Biopharma's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Statera Biopharma Outstanding Bonds
Statera Biopharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Statera Biopharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Statera bonds can be classified according to their maturity, which is the date when Statera Biopharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our pink sheet analysis tools, you can find out how much better you can do when adding Statera Biopharma to your portfolios without increasing risk or reducing expected return.Did you try this?
Run USA ETFs Now
USA ETFsFind actively traded Exchange Traded Funds (ETF) in USA |
| All Next | Launch Module |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Other Consideration for investing in Statera Pink Sheet
If you are still planning to invest in Statera Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Statera Biopharma's history and understand the potential risks before investing.
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |